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To support the role ofDISC1 in human psychiat-
ric disorders, we identified and analyzed two
independently derived ENU-induced mutations
in Exon 2 of mouse Disc1. Mice with mutation
Q31L showed depressive-like behavior with
deficits in the forced swim test and other mea-
sures that were reversed by the antidepressant
bupropion, but not by rolipram, a phosphodies-
terase-4 (PDE4) inhibitor. In contrast, L100P
mutant mice exhibited schizophrenic-like be-
havior, with profound deficits in prepulse inhibi-
tion and latent inhibition that were reversed by
antipsychotic treatment. Both mutant DISC1
proteins exhibited reduced binding to the
known DISC1 binding partner PDE4B. Q31L
mutants had lower PDE4B activity, consistent
with their resistance to rolipram, suggesting de-
creased PDE4 activity as a contributory factor
in depression. This study demonstrates that
Disc1 missense mutations in mice give rise to
phenotypes related to depression and schizo-
phrenia, thus supporting the role of DISC1 in
major mental illness.
INTRODUCTION
Schizophrenia is a common, chronic, and severely debili-
tating form of mental illness, typified by positive symp-
toms of hallucinations, delusions, and thought disorder;
negative symptoms of decreased motivation, altered ex-
pressivity, and an inability to experience pleasure (anhe-
donia); selective cognitive deficits in attention, learning,
and memory; and comorbid features of depression, sub-stance abuse, and suicide (Ross et al., 2006; Lewis and
Gonzalez-Burgos, 2006). It ranks as one of the leading
causes of disability worldwide, but current treatments
are at best palliative and will remain so until the molecular
basis is better understood (Insel and Scolnick, 2006;
Lewis and Gonzalez-Burgos, 2006). There is a strong
genetic component to the illness. Indeed, over 130 genes
have been reported to predispose to schizophrenia, but
few have been replicated, and fewer still have biological
support (Ross et al., 2006). One candidate is Disrupted
in schizophrenia 1 (DISC1), which was originally identified
at one breakpoint of a chromosomal t(1;11) (q42.1;q14.3)
translocation that cosegregates in a large Scottish family
with major mental illness, including schizophrenia, bipolar
disorder, and major depression (Millar et al., 2000; Black-
wood et al., 2001).
Multiple independent linkage and association studies in
diverse populations have since reported preliminary evi-
dence in support of DISC1 as a more generalized risk
factor in schizophrenia and mood disorders (reviewed in
Hennah et al. [2006], Porteous et al. [2006]). DISC1 has
also been reported to associate with impairedmemory, re-
duced gray matter density and volume, and abnormal hip-
pocampal volume and function (Callicott et al., 2005; Can-
non et al., 2005; Hennah et al., 2005; Hashimoto et al.,
2006). Although some of these associations have been re-
lated to known DISC1 missense polymorphisms, to date,
evidence for consistent allelotypic or genotypic associa-
tion and robust associateddysfunctionofDISC1 is lacking,
and thus the criteria for causality have not been met.
A consistent pattern has emerged from DISC1 expres-
sion studies in the human, primate, and rodent brain,
with evidence for developmental regulation and high pro-
tein levels in subregions, particularly the hippocampus,
implicated in the pathogenesis of psychiatric disorders
(Austin et al., 2003, 2004; Miyoshi et al., 2003; Ozeki
et al., 2003; Schurov et al., 2004). DISC1 functions as
a molecular scaffold, interacting with multiple proteinsNeuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc. 387
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Disc1 Missense Mutations in Micerequired for neuronal migration, neurite outgrowth, signal
transduction, cyclic adenosine monophosphate (cAMP)
signaling, cytoskeletal modulation, and translational regu-
lation (reviewed in Porteous et al. [2006], Ross et al. [2006],
Camargo et al. [2007]). Among the known DISC1 binding
partners, cAMP-hydrolyzing PDE4B is particularly note-
worthy on four counts. First, the PDE4B gene was found
to be disrupted by a translocation in two related individ-
uals with psychosis (Millar et al., 2005). Second, PDE4 iso-
forms are targets of inhibition by rolipram (Wachtel, 1983)
and linked through animal models to learning, memory,
and mood (Arguello and Gogos, 2006; O’Donnell and
Zhang, 2004). Third, PDE4B activity is dynamically regu-
lated by DISC1 (Millar et al., 2005). Fourth, PDE4 isoforms
are now well recognized as underpinning compartmental-
ized cAMP signaling (Di Benedetto et al., 2006) through
being tethered to specific scaffold proteins such as b-
arrestin and RACK1 (Houslay et al., 2005).
We have proposed that allelic variation of DISC1 might
have pleiotropic effects, depending on the location and
type of sequence change, the selective effects these
may have on specific protein interactions, and the conse-
quential impact on the DISC1 pathway as this relates to
normal and dysfunctional brain development, biochemis-
try, and behavior (Porteous et al., 2006). Further clinical
studies can address some of the outstanding questions,
but this approach is restricted by the limited scope for
experimentation and access to appropriate tissue. We
therefore sought to establish mutations in the mouse
Disc1 gene and then use cognate measures of behavior,
brain anatomy, neurophysiology, and pharmacological re-
sponse to support and extend the clinical findings. The
method of choice was N-nitroso-N-ethylurea (ENU) muta-
genesis, which induces point mutations at a high locus-
specific rate (Coghill et al., 2002). ENU-induced mutations
inDisc1, along with the recently discovered 25 bp deletion
that arose spontaneously in the 129 strain (Clapcote and
Roder, 2006; Koike et al., 2006), would form a series of
mutant alleles through which to elucidate DISC1 function
in the laboratory mouse. We report the differential impacts
of two such mutations, one producing a depressive-like
phenotype and the other resulting in a schizophrenic-like
phenotype in mice with a C57BL/6J genetic background.
RESULTS
Identification of Missense Mutations in Disc1
DISC1 isoforms are encoded by 13 major exons, of which
Exon 2 at 955 bp is the longest. Exon 2 is present in all
known splice isoforms and encodes most of the protein
head domain, which we have shown previously in the hu-
man to interactwithPDE4B (Millar et al., 2005). Association
between schizophrenia, schizoaffective disorder, and as-
pects ofworkingmemory in the humanhavebeen reported
for Exon 2-spanning haplotypes (Cannon et al., 2005; Hen-
nah et al., 2005; Maeda et al., 2006). We screened Exon 2
of Disc1 in 1686 F1 progeny of ENU-mutagenized C57BL/
6JJcl males and untreated DBA/2JJcl females, and de-388 Neuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc.tected two independently-derived missense mutations.
Mutant transcript Disc1Rgsc1393 has a 127A/T transver-
sion (Figure 1B) resulting in amino acid exchange Q31L
(Figure 1A), and mutant transcript Disc1Rgsc1390 has
a334T/Ctransition (Figure 1B) resulting in amino acid ex-
change L100P in the encoded protein (Figure 1A). The
Exon 2 sequences of the C57BL/6JJcl and DBA/2JJcl pa-
rental strains are identical (data not shown), suggesting
that both mutations arose as a result of ENU administra-
tion. Heterozygous N2 backcross progeny of the founder
31L and 100P heterozygous (DBA/2JJcl 3 C57BL/6JJcl)
F1 males and wild-type C57BL/6JJcl females were back-
crossed through the male and female lines to C57BL/6J
for four generations (N3–N6) before heterozygotes with
a predominantly C57BL/6J genetic background (average
of 98.4375% at N6) were intercrossed to generate ho-
mozygous (31L/31L; 100P/100P), heterozygous (31L/+;
100P/+), and compound heterozygous (31L/100P) mu-
tants for phenotypic testing, whichwere viable and grossly
indistinguishable from their wild-type (+/+) littermates.
31L/+ (Rgsc1393) and 100P/+ (Rgsc1390) mice are avail-
able from the RIKEN BioResource Center (www.brc.
riken.jp/lab/animal/en/gscmouse.shtml).
Schizophrenic-like Phenotype in 100P Disc1
Mutant Mice
Deficits in attention and information processing are con-
sidered a central feature of schizophrenia, which lead to
stimulus overload, cognitive fragmentation, and thought
disorders (Perry and Braff, 1994). Prepulse inhibition
(PPI) and latent inhibition are the most common methods
to quantify information-processing deficits in schizophre-
nia with a reasonable amount of face, predictive, and con-
struct validity (Geyer and Ellenbroek, 2003), and they can
be used in both human and animal experiments (Arguello
and Gogos, 2006).
PPI is the degree to which the acoustic startle response
is reduced when the startle-eliciting stimulus is preceded
by a brief low-intensity stimulus that does not elicit a startle
response. We found that 100P/100P, 100P/+, 31L/31L,
and 31L/100P mice had lower PPI than +/+ mice
(Figure 2A). In the absence of a prepulse, the amplitude
of the acoustic startle response was lower in 100P/100P,
100P/+, and 31L/100P mice than in +/+ mice (see
Figure S1 in the Supplemental Data available with this ar-
ticle online), while 100P/100P mice also had lower startle
reactivity to a wide range of startle intensities (Figure S1).
We found no correlation between startle response and PPI
in 100P/100P mice (r = 0.16, p = 0.14). The lower PPI of
100P/100P and 100P/+ mice was not a result of impaired
hearing, as the auditory brainstem response (ABR) thresh-
old at 16 kHz was not different between 100P/100P (40 ±
2.6) and +/+ mice (46 ± 5.1).
The typical antipsychotic haloperidol, a dopamine D2
receptor antagonist, and the atypical antipsychotic cloza-
pine, an antagonist of both dopamine and serotonin re-
ceptors, both partially alleviated the pronounced deficit
of 100P/100P mice. Clozapine also increased PPI in
Neuron
Disc1 Missense Mutations in MiceFigure 1. Missense Mutations in Mouse Disc1
(A) Alignment of the predicted disrupted in schizophrenia 1 protein sequences of mouse Disc1 (ENSMUSP00000074147) and human DISC1
(ENSP00000295051) using the Clustal W 1.81 program. Residues identical between mouse and human have a gray background. The codon mutated
in eachDisc1mutant mouse line is shown in red text and indicated by a red arrow. Nonsynonymous SNPs in humanDISC1 associated with increased
risk for major depression (Hashimoto et al., 2006), bipolar disorder (Maeda et al., 2006), schizophrenia (Callicott et al., 2005; Cannon et al., 2005), or
schizoaffective disorder (Hodgkinson et al., 2004) are shown in green text and indicated by green arrows. The breakpoint of the translocation that
segregates with psychiatric illness in a large Scottish family (Millar et al., 2000) is indicated by a vertical bar (j) labeled BP. Dashes indicate alignment
gaps. Numbers to the right of the alignment show the amino acid position of the corresponding aligned sequence. Exons are indicated by alternating
black and blue text.
(B) DNA sequence chromatograms showing point mutations in Disc1 Exon 2. Transversion 127A/T is predicted to convert residue 31 from CAG
glutamine (Gln) to CTG leucine (Leu). Transition 334T/C is predicted to convert residue 100 from CTC leucine (Leu) to CCC proline (Pro).100P/+ and +/+ mice, but 31L/+ and 31L/31L mice did not
respond to either antipsychotic (Figure 2B). The antide-
pressant bupropion, a dopamine and norepinephrine re-
uptake inhibitor, abolished the mild PPI deficit of 31L/
31L mice but was not effective against the severe PPI im-
pairment of 100P/100P or 100P/+ mice (Figure 2B). Con-
versely, the PDE4 inhibitor rolipram increased the PPI of
100P/100P and 100P/+ mice to the level of +/+ mice but
did not reverse the milder PPI deficit of 31L/31L mice
(Figure 2B). None of the drugs affected the acoustic startle
response (Table S1).Latent inhibition (LI) is the phenomenon by which prior
exposure to a nonrewarding conditioned stimulus de-
creases the salience of the conditioned stimulus (CS)
when it is later paired with an unconditioned stimulus
(US) (Weiner, 2003). The drinking performance of mutant
mice was normal, as genotypes neither differed in drink-
ing behavior during 5 days of training prior to testing
(Figure S1) nor in time to complete licks 50–75 before
CS onset during testing. LI was disrupted in 100P/100P,
100P/+, and 31L/31L mice pre-exposed to the CS
(Figure 2C). A strong CS-US association was exhibitedNeuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc. 389
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Disc1 Missense Mutations in Miceby non-pre-exposed mice of all genotypes (Figure 2C),
suggesting that the LI disruption was not due to a gross
cognitive deficit but a specific information-processing
deficit. The administration of clozapine abolished the dis-
ruption of LI in 100P/100P mice but had no effect on LI in
the other genotypes (Figure 2D).
In a novel, open field, 100P/100P mice displayed
greater horizontal locomotion throughout the 30 min test-
ing period (Figure 2E), whereas vertical locomotion (rear-
ing) was greater only during the first 10 min (Figure S1).
No differences in locomotion were displayed by the other
mutants. Clozapine-treated mice of all genotypes dis-
played lower horizontal locomotion than vehicle-treated
counterparts (Figure 2F). In the elevated plus maze,
a test of anxiety (Rogers and Cole, 1994), the duration of
time on the open arms was not different between geno-
types (Figure S1), suggesting that open field locomotion
was not affected by altered anxiety levels.
We assessed working memory using a discrete paired-
trial variable-delay T-maze task (Aultman and Moghad-
dam, 2001). When this task was previously applied to
Disc1 deletion carriers, they performed normally during
training but showed a deficiency across all choice delay
intervals in the working memory test (Koike et al., 2006).
We found that 100P/100P mice required more trainingthan +/+ and 31L/31L mice to reach 70% correct re-
sponses on 3 consecutive days (Figure 2G). In the working
memory test, 31L/31L and 100P/100P mutants had fewer
correct responses at shorter (5 s and 10 s) but not longer
(30 s) choice delay intervals (Figure 2H). In the Morris wa-
ter maze, a test of spatial learning andmemory, the perfor-
mance of 31L and 100P mutants was not different from
that of +/+ mice (Figure S1), suggesting that reference
memory was not affected by the missense mutations.
Depressive-like Phenotype in 31L Disc1Mutant Mice
In the forced swim test (FST), a well-established paradigm
to detect depressive-like behavior in rodents (David et al.,
2003), the duration of floating immobile on the surface of
the water was increased in 31L/31L mutants (Figure 3A).
As antidepressant drugs have been shown to decrease
the duration of immobility (David et al., 2003), this measure
is used as an index of behavioral despair. We found that
bupropion and rolipram both reduced immobility time in
+/+ mice, but only bupropion significantly reduced immo-
bility time in 31L/31L mice (Figure 3B). In a 2 day FST pro-
cedure, a new cohort of 31L/31L, 31L/+, and +/+ mice all
had greater immobility on day 2 than on day 1 (Figure S2),
suggesting that all genotypes were exhibiting learned
helplessness.However, 31L/31LmutantsdisplayedhigherFigure 2. Schizophrenic-like Behaviors in 31L and 100P Mutant Mice
(A) Prepulse inhibition of acoustic startle response. PPI assay using a combination of startle (120 dB) and three prepulse levels (69 dB, 73 dB, and
81 dB) in 31L/31L (n = 24), 31L/+ (n = 24), 100P/100P (n = 21), 100P/+ (n = 20), +/+ (n = 21), and 31L/100P (n = 10) mice. PPI is expressed as the
mean percent reduction (±SEM) in startle amplitude at all three prepulses. Higher y axis values represent greater percent PPI. There were significant
effects of genotype (F(5,120) = 11.17, p = 0.0009), prepulse intensity (F(2,240) = 4.92, p = 0.008), and genotype-prepulse interaction (F(10,240) = 2.70, p =
0.004). *p < 0.05; **p < 0.01; ***p < 0.001 versus +/+ mice.
(B) Pharmacological responses in PPI assay. Mean effects of clozapine (3mg/kg), haloperidol (0.4 mg/kg), bupropion (4mg/kg), and rolipram (0.5 mg/
kg) on PPI (±SEM) in 31L/31L (n = 10–16), 31L/+ (n = 10–24), 100P/100P (n = 11–17), P/+ (n = 10–22), and +/+ (n = 11–16) mice. There were significant
effects of genotype (F(4,290) = 23.40, p = 10
6), drug (F(4,290) = 6.22, p = 0.00006), and genotype-drug interaction (F(16,290) = 5.16, p = 6 3 10
5). *p <
0.05; **p < 0.01; ***p < 0.001 versus vehicle-treated mice within each genotype. ##p < 0.01; ###p < 0.001 versus vehicle-treated +/+ mice.
(C) Latent inhibition of fear conditioning. Mean suppression ratios (±SEM) of 31L/31L (n = 9 PE, 8 NPE), 31L/+ (n = 16 PE, 16 NPE), 100P/100P (n = 7
PE, 7 NPE), 100P/+ (n = 11 PE, 11 NPE), and +/+ (n = 13 PE, 8 NPE) mice pre-exposed (PE) and non-pre-exposed (NPE) to the CS. LI is indicated by
a lower suppression of drinking (higher suppression ratio) in PE compared to NPE mice, and was exhibited only by 31L/+ and +/+ mice. There were
significant effects of genotype (F(4,96) = 4.22, p = 0.003) and pre-exposure (F(1,96) = 11.21, p = 0.001). There was no difference between genotypes in
the time to complete licks 50–75 (period A; before CS onset). *p < 0.05; **p < 0.01 versus PE mice within each genotype. ### p < 0.001 versus PE +/+
mice.
(D) Clozapine response in LI assay. Mean suppression ratios (±SEM) of vehicle- and clozapine-treated (PE, NPE) mice: 31L/31L (n= 6, 6 and n = 6, 6),
100P/100P (n = 6, 6 and n = 7, 6), 100P/+ (n = 6, 6 and n = 11, 9), and +/+ (n = 7, 10 and n = 8, 7). Clozapine rescued the LI deficit of 100P/100P mice
only. Clozapine (3mg/kg, 30min, i.p.) was administrated in both the pre-exposure and conditioning stages. There were significant effects of genotype
(F(3,102) = 3.1, p = 0.03), drug (F(1,102) = 7.8, p = 0.006), pre-exposure (F(1, 102) = 39.5, p = 0.0001), and genotype 3 drug 3 pre-exposure interactions
(F(3,102) = 7.7, p = 0.0001). **p < 0.01; ***p<0.001 versus PEmice within each genotype and drug treatment. #p < 0.05 versus vehicle-treated PE-100P/
100P mice.
(E) Horizontal locomotion in the open field. Mean number of beam breaks (±SEM) in 5 min bins by 31L/31L (n = 6), 31L/+ (n = 17), 100P/+ (n = 7), 100P/
100P (n = 9), and +/+ (n =14) mice. There were significant effects of genotype (F(4,48) = 4.0, p = 0.008) and time interval (F(5, 240) = 6.7, p = 0.00007).
Horizontal locomotion was higher in 100P/100Pmutants at all time points (p < 0.05 at 10–15, 20–25, and 25–30 min, p < 0.01 at 0–5, 5–10, and 15–20
min). 100P/+, 31L/+, and 31L/31L mutants were not significantly different from +/+ mice. *p < 0.05; **p < 0.01 versus +/+ mice.
(F) Clozapine effect on open field horizontal locomotion. Mean number of beam breaks (±SEM) in 5 min bins by vehicle- and clozapine-treated 31L/
31L (n = 6, 6), 100P/100P (n = 8, 10), and +/+ (n = 7, 8) mice. There was a significant effect of genotype (F(1, 36) = 27.8, p = 63 10
6), drug (F(1, 36) = 14.2,
p = 2.83 105), and genotype3 time interval interaction (F(10, 180) = 2.3, p = 0.01). Clozapine reduced the horizontal locomotion in the open field of all
genotypes. *p < 0.05; **p < 0.01; ***p < 0.001 versus vehicle-treated mice within each genotype. #p < 0.05 versus vehicle-treated +/+ mice.
(G) T-maze alternation training. Mean percentage of correct responses (±SEM) during the discrete paired-trial delayed alternation training by 31L/31L
(n = 9), 100P/100P (n = 8), and +/+ (n = 8)mice. Therewas a significant effect of genotype (F(2,22) = 7.56, p = 0.003) on correct responses. Note that the y
axis starts at 50% correct responses, which represents the baseline response accuracy expected by chance. *p < 0.05 versus +/+ mice.
(H) Working memory performance with different delay intervals. Mean percentage of correct responses (±SEM) by 31L/31L (n = 9), 100P/100P (n = 8),
and +/+ (n = 8)mice in theworkingmemory test with choice delay intervals of 5 s, 15 s, and 30 s. There was a significant effect of genotype (F(2,22) = 9.6,
p = 0.001) on correct responses. *p < 0.05; **p < 0.01 versus +/+ mice.Neuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc. 391
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Disc1 Missense Mutations in MiceFigure 3. Behaviors of 31L Mutants Analogous to Symptoms of Depression
(A) Forced swim test. Mean duration of immobility (±SEM) of 31L/31L (n = 10), 31L/+ (n = 20), 100P/100P (n = 13), 100P/+ (n = 21), and +/+ (n = 27)mice.
There was a significant effect of genotype (F(4,86) = 3.3, p = 0.02). Immobility time was longer in 31L/31L mice. *p < 0.05 versus +/+ mice.
(B) Pharmacological responses in the FST. Mean effects of bupropion (acute administration; 4 mg/kg, 30 min, i.p.) and rolipram (daily administration
for 8 days; 0.5 mg/kg, 30 min, i.p.) on duration of immobility (±SEM) in 31L/31L (n = 7, 9) and +/+ (n = 6, 8) mice. There were significant effects of drug
(F(2,38) = 5.1, p = 0.01) and genotype (F(1,38) = 10.6, p = 0.0003). Bupropion, but not rolipram, significantly decreased immobility duration in 31L/31L
mice (p = 0.01). However, both drugs had antidepressant effects on +/+ mice. *p < 0.05, **p < 0.01 versus vehicle-treated mice within each genotype.
##p < 0.01 versus vehicle-treated +/+ mice.
(C) Sociability. Mean duration of time (±SEM) in the chamber with the stranger (‘‘stranger side’’) than in the opposite chamber (‘‘empty side’’). Unlike
+/+ (n = 6), 100P/+ (n = 7), and 100P/100P (n = 7) mice, 31L/+ (n = 8) and 31L/31L (n = 6) mice failed to demonstrate a preference for social proximity by
spending significantly more time in the stranger side. There were significant effects of genotype (F(4, 28) = 9.62, p = 5.7 3 10
5) and presence of
‘‘stranger 1’’ (F(1, 28) = 4.1 3 10
6). *p < 0.05, **p < 0.01 versus empty side within each genotype.
(D) Social novelty. Mean duration of time (±SEM) in the chamber with the unfamiliar mouse from the sociability phase (‘‘stranger 1’’) and in the opposite
chamber with a new unfamiliar mouse (‘‘stranger 2’’). Unlike +/+ (n = 6), 100P/+ (n = 7), and 100P/100P (n = 7) mice, 31L/+ (n = 8) and 31L/31L (n = 6)
mice failed to demonstrate a preference for social novelty by spending significantly more time in the chamber with stranger 2, rather than the more
familiar stranger 1. There were significant effects of genotype (F(4, 28) = 7.88, p = 0.0002), presence of new partner (stranger 2) (F(1, 28) = 5.97, p = 0.02),
and genotype 3 presence of new partner interaction (F(4, 28) = 4.79, p = 0.005). *p < 0.05 versus ‘‘stranger 1’’ side within each genotype.
(E) Sucrose consumption test. Preference for a 10% sucrose solution over water is shown as the mean percentage (±SEM) of sucrose solution in-
gested relative to the total amount of liquid consumed. There were significant effects of genotype (F(2,17) = 28.43, p = 0.0001), test day (F(3,51) =
5.39, p = 0.003), and genotype3 test day interaction (F(6, 51) = 8.35, p = 53 10
6) on sucrose preference. 31L/31L (n = 6) mice consumed significantly
less of the sucrose solution relative to water than +/+ (n = 8) and 100P/100P (n = 6) mice on day 2 (p < 0.01), day 3 (p < 0.05), and day 4 (p < 0.01),
consistent with a lower responsiveness to rewards. *p < 0.05, **p < 0.01 versus +/+ mice.392 Neuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc.
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Disc1 Missense Mutations in Miceimmobility than +/+ and 31L/+ mice on both days
(Figure S2), suggesting an effect of despair rather than
fatigue.
Next, we investigated whether the depressive-like be-
havior of 31L/31L mice in the FST was also exhibited in
the less-aversive social interaction (Moy et al., 2004) and
reward responsiveness (Pothion et al., 2004) tests, deficits
in which are analogous to key symptoms of depression
(American Psychiatric Association, 1994). In the sociability
phase of the social interaction test, we found that +/+mice
and 100P mutants spent more time in a chamber contain-
ing an unfamiliar mouse inside a cylinder than in the oppo-
site chamber containing an empty cylinder, whereas 31L
mutants did not (Figure 3C). In the social novelty phase
of the test, +/+ mice and 100P mutants demonstrated
a shift in preference, spending more time in a chamber
containing a new unfamiliar mouse (‘‘stranger 2’’) than in
the chamber containing the original unfamiliar mouse
from the sociability phase (‘‘stranger 1’’), whereas again
31L mutants did not (Figure 3D). The lower social interac-
tion of 31L mutants was not a result of diminished olfac-
tion, as we found that the time required to find buried
food in an olfaction test was not different between geno-
types (Figure S2).
We tested reward responsiveness by measuring su-
crose consumption. Low responsiveness to rewards,
such as a sweet taste, is comparable to anhedonia, the
core symptom of the melancholic subtype of depression
(Willner, 1997). When presented with two drinking bottles,
one containing water and the other containing 10% su-
crose, 31L/31L mice consumed significantly less of the
sucrose solution relative to water than +/+ and 100P/
100P mice on the last 3 days of the 4 day test (Figure 3E),
which is consistent with a lower responsiveness to re-
wards. We found no evidence for a difference in taste
sensitivity in 31L/31L mice (Figure S2).
Reduced Brain Volume in 31L and 100P Disc1
Mutant Mice
Structural and functional imaging studies have estab-
lished that brain anatomical abnormalities are a consistent
feature of schizophrenia (Ross et al., 2006). Recent evi-
dence suggests that this is also true in depression
(Meyer-Lindenberg and Weinberger, 2006) and bipolar af-
fective disorder (Hasler et al., 2006). We therefore exam-
ined 31L and 100P mutants for evidence of structural dif-
ferences in the brain. Magnetic resonance imaging (MRI)
revealed reductions in overall brain volume of 13% in
100P/100P and 100P/+ mice and 6% in 31L/31L and
31L/+ mice (Figure 4A). These overall reductions were ac-
companied by tissue contraction in the cortex, entorhinal
cortex, thalamus, and cerebellum of 100P and 31L mu-
tants (Figures 4B and 4C).
DISC1 Protein Levels in 31L and 100P Disc1
Mutant Brain
To assess the effects of the 31L and 100P mutations on
DISC1 protein levels in the brain, we measured DISC1 im-munoreactivity in brain extracts from 31L/31L, 100P/
100P, and +/+ mice. An antibody that recognizes an epi-
tope at the C-terminal region of DISC1, unaffected by
both missense mutations, detected major bands of 71,
75, and 105 kDa, plus several minor bands, in all geno-
types (Figure S3). The three major bands match compara-
bly sized bands previously detected in adult mouse brain
using different DISC1 C-terminal antibodies, the 105
kDa band likely representing full-length DISC1 (Schurov
et al., 2004; Ishizuka et al., 2006). This suggests that
both Disc1 mutant lines express all of the major DISC1
isoforms. Densitometry analysis of the 71, 75, and
105 kDa signals revealed no significant differences
between genotypes.
Subcellular Distribution of DISC1 and PDE4B
in Disc1 Mutant Brain
To examine effects of the 31L and 100P mutations on the
subcellular distribution of DISC1, we prepared subcellular
fractions from +/+, 31L/31L, and 100P/100P mouse
brains. Immunoblotting of synaptosomes and postsynap-
tic density (PSD) fractions revealed that the 71 and 75
kDa DISC1 isoformswere predominantly expressed in pu-
rified synaptosomes, PSD1, and PSD2 fractions, but not
enriched within the core PSD fraction, PSD3 (Figure S3).
In addition, an immunoreactive band at200 kDa was de-
tected in all PSD fractions (Figure S3). This200 kDa spe-
cies may represent an SDS-resistant DISC1 complex or
an additional DISC1 isoform. We also investigated the dis-
tribution of PDE4B in these fractions, since we have previ-
ously demonstrated a robust interaction between PDE4B
and DISC1 in human cells (Millar et al., 2005). PDE4B was
associated with synaptosomes and all PSD fractions
(Figure S3). In addition, we analyzed P3 (microsomes
and light membranes) and ER-G (a mixture of ER, Golgi,
and plasma membranes) fractions, and immunoblotting
analysis detected the 71 and 75 kDa DISC1 isoforms
in both fractions (Figure S3). PDE4B was also abundant
in both fractions (Figure S3). We did not attempt to analyze
nuclear fractions due to the unavoidable contamination of
this fraction with cellular debris. There was no detectable
difference in distribution of DISC1 or PDE4B in any of the
fractions tested from +/+, 31L/31L, and 100P/100P mice.
Reduced PDE4B Binding to Mutant DISC1
The N-terminal head domain of DISC1 is important for in-
teraction with PDE4B, and we previously demonstrated
that amino acids 220–283 are involved in binding (Millar
et al., 2005). However, a peptide array profiling approach
has since demonstrated that multiple regions of human
DISC1 act as contact sites for PDE4B, including additional
sites within the head domain that encompass the posi-
tions of the mouse 31L and 100P mutations (M.D.H., un-
published data). We therefore investigated the possibility
that these missense mutations influence binding between
DISC1 and PDE4B. When DISC1 and PDE4B were exog-
enously coexpressed in HEK293 cells, we found that both
mutations significantly reduced binding between DISC1
Neuron
Disc1 Missense Mutations in MiceFigure 4. Reduced Brain Volume in 31L and 100P Mutant Mice
(A) Composite mean brains of the wild-type (+/+, n = 6), 100P (100P/100P, n = 6; 100P/+, n = 6), and 31L (31L/31L, n = 6; 31L/+, n = 6) groups after
nonlinear registration. The overall volume of the 100P and 31L mutant brains was lower by 13% (U = 7, p = 0.019) and 6% (U = 10, p = 0.05), respec-
tively.
(B) Relative contraction of brain regions. Differences in Jacobian determinants in the 31L (p = 0.046) and 100P (p = 0.006) groups as compared to the
wild-type group. The contraction around the cortex is noticeable while the white matter tracts remain unchanged. The maps feature a spatially similar
pattern between the two groups, though the 100P group has greater contraction.
(C) Thresholded results from the Mann-Whitney U test. Values of U (0–11) are represented by colors indicated in the spectrum to the right.
(D) Box plot of tissue contraction (normalized to themean Jacobian of the +/+ group) of a single voxel in the cortex. The pattern of tissue contraction is
clearly evident in the graph, as is the relative similarity between homozygotes and heterozygotes for each mutation.and PDE4B, with the 100P mutation exerting the greatest
effect (Figure 5). We observed the same outcome with the
long isoforms PDE4B1 and PDE4B3. However, the degree
of binding was variable, particularly with the 31Lmutation,
suggesting that mutant DISC1 binding to PDE4B is influ-
enced by the effects of unknown fluctuating cellular
factors.
Lower PDE4B Activity in 31L Disc1 Mutant Brain
We previously reported that the head domain of DISC1
binds to the UCR2 domain of PDE4B in a cAMP-depen-
dent fashion (Millar et al., 2005) and proposed a model
in which DISC1 binds to an unphosphorylated low-activity
form of PDE4B that is released as a PKA-phosphorylated394 Neuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc.high-activity form in response to cAMP upregulation, thus
providing a negative-feedback mechanism to modulate
cAMP levels (Millar et al., 2005). Given this dynamic in-
teraction and the different responses of 31L and 100P
mutants to the PDE4 inhibitor rolipram, we determined
the relative amounts of DISC1 and PDE4B protein and
PDE4B catalytic activity in 31L/31L, 100P/100P, and +/+
brain extracts. Intriguingly, although we saw no difference
in the amount of PDE4B protein between Disc1 mutant
and wild-type brains (Figure S3), we did see a striking
50% reduction in PDE4B activity specifically in 31L/31L
brains (Figure 5), indicating that the activity status of
PDE4B is altered in this mutant line. This reduction in
PDE4B activity is consistent with the resistance of 31L
Neuron
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(A and B) Reduced PDE4B binding to mutant
DISC1.
(A) Association between exogenously ex-
pressed PDE4B isoforms and mutant DISC1
expressed as percentage of wild-type. Five in-
dependent binding assays were performed
with each mutant in parallel, using PDE4B1
(B1) or PDE4B3 (B3). Numbers within bars refer
to each independent experiment. The degree
of binding was variable between experiments
for eachmutant, but bothmutants showed sim-
ilar alterations in binding within each experi-
ment. Binding of PDE4B isoforms to 31L and
100P mutant DISC1 was significantly reduced.
*p<0.05, ***p<0.001.
(B) Typical blot of PDE4B1 immunoprecipita-
tions probed with anti-DISC1 (upper) and
pan-PDE4B (lower) antibodies. The bands
shown correspond to the predicted 100 kDa
DISC1 and 80 kDa PDE4B1 forms.
(C) Lower PDE4B activity in 31L mutant brain.
Activity of PDE4B in the brains of 31L/31L
(n = 4) and 100P/100P (n = 4) mice. Activity measurements are means (±SEM) for three separate experiments. Results are expressed as a percentage
of wild-type control (n = 4) to minimize interexperiment variation. Mean PDE4B activity in 31L/31L brain tissue was reduced by 47.98% ± 6.70%.
****p < 0.00001.mutants and the contrasting sensitivity of 100P mutants
and wild-type mice to treatment with rolipram (Figure 2B).
DISCUSSION
ENU Induced Mutations in Disc1, Predicted
Functional Consequences,
and Pathophysiological Mechanisms
In our screen ofDisc1 Exon 2, twomutations were found in
1686 mice, a rate comparable with the reported genome-
wide average for a functional mutation in any single locus
of 1 in 500–1500 F1 mice (Justice et al., 1999). Based on
this average rate, each founder Disc1 mutant was ex-
pected to be heterozygous for 24 additional functional
mutations randomly distributed across the25,000 genes
in the mouse genome. By backcrossing each Disc1muta-
tion to the C57BL/6J strain for five generations (N2–N6),
we reduced the expected number of additional heterozy-
gous mutations in eachmutant line to 0.75 (Michaud et al.,
2005). Given that only 25% of these 0.75 additional muta-
tions are expected to be carried by both mice of a sixth
generation intercross breeding pair (Michaud et al.,
2005), it is highly unlikely that any of their progeny used
for phenotypic testing would be homozygous for a muta-
tion in any gene other than Disc1. Moreover, the use of
multiple breeding pairs having different combinations of
additional mutations and the free segregation of such
unlikely mutations across all Disc1 genotypes within their
progeny effectively eliminates the chance of falsely
associating the observed mutant phenotypes with the
missense mutations in Disc1.
These mutations, on a C57BL/6J background, are thus
quite distinct from the spontaneous 25 bp deletion in Exon6 of Disc1 discovered in the 129S6/SvEv substrain (Koike
et al., 2006), and subsequently in all other 129mouse sub-
strains (Clapcote and Roder, 2006). Koike et al. (2006)
reported impairment in a single working memory test,
but no gross brain morphology, altered open field activity,
or PPI deficit when the Disc1 deletion was crossed onto
a C57BL/6J background. This preliminary molecular and
behavioral characterization merits further analysis, partic-
ularly as a recent collaborative study using multiple vali-
dated DISC1 antibodies suggests that all but one possible
isoforms of DISC1 are intact and normally expressed from
the deletion allele (Ishizuka et al., 2007).
The three-dimensional structure of DISC1 has yet to be
solved, but the nature of the Q31L and L100P amino acid
exchanges gives clues to their likely effects. Glutamine (Q)
is hydrophilic and would normally be found on the outer
surface of a protein. This is probably true in the case of
Q31, as it is immediately adjacent to a predicted bipartite
nuclear localization signal (RRRLTRRP). The 127A/T
transversion resulted in Q31 being replaced by a leucine
(L), a hydrophobic amino acid that would normally be ex-
pected to be located within the interior of a protein. The
334T/C transition resulted in L100 being replaced by
a proline (P), a hydrophobic amino acid whose ring struc-
ture is known to cause a sharp transition in polypeptide
chain direction, which can either interrupt the formation
of or terminate any regular structural feature. Thus, such
missense mutations most likely result in distinct structural
alterations in DISC1.
ThesemissenseDisc1mutantsmay thereforemodel the
putative (but yet to be formally established) missense mu-
tations, such as Ser704Cys, that are thought to account
for a proportion of the liability to schizophrenia and relatedNeuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc. 395
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Disc1 Missense Mutations in Micepsychiatric disorders attributable to DISC1 variation (Por-
teous et al., 2006). To the best of our knowledge, however,
there are no directly comparable missense mutations in
Exon 2 of human DISC1.
Neuroanatomical Abnormalities
Neuroanatomical abnormalities have been consistently
reported following brain imaging of schizophrenics, bipo-
lar subjects, and their ‘‘high-risk’’ relatives (Strakowski
et al., 1999; McIntosh et al., 2007; Ross et al., 2006),
and there is preliminary evidence awaiting validation that
specific DISC1 polymorphisms associate with structural
and functional brain alterations in schizophrenic and nor-
mal subjects (Callicott et al., 2005; Cannon et al., 2005;
Hashimoto et al., 2006). Consistent with this, MRI de-
tected neuroanatomical abnormalities in both Disc1 mu-
tant lines. The reductions in overall brain volume of 6%
in 31L mutants and 13% in 100P mutants (Figure 4) corre-
spond well with observations of small but significant re-
ductions in brain volume in patients with schizophrenia
(Lawrie and Abukmeil, 1998; Wright et al., 2000). The sim-
ilarity in the magnitude of the brain volume and PPI reduc-
tions associated with each mutation suggests that these
effects are interrelated. 31L and 100P mutants both
showed contraction of the cortex, entorhinal cortex, thal-
amus, and, particularly, the cerebellum (Figure 4), all of
which are brain regions previously implicated in the path-
ophysiology of schizophrenia (Harrison and Weinberger,
2005; Konarski et al., 2005; Ross et al., 2006). The con-
traction of the cerebellum in both Disc1 mutants provides
support for the role of this brain region in the pathophysi-
ology of psychiatric disease, as suggested by preliminary
evidence that patients with depression and schizophrenia
may share similar structural (volumetric reductions) and
functional (baseline hyperactivity) abnormalities in the cer-
ebellum (Konarski et al., 2005). Our observations are also
consistent with the evidence thatDisc1 is developmentally
regulated and expressed in all of the affected brain regions
(Schurov et al., 2004; Ross et al., 2006).
Behavioral Abnormalities
Deficits in sensory processing of distracting incoming in-
formation and excessive stimuli may contribute to the
cognitive impairments and auditory hallucinations that
characterize many schizophrenic patients (Swerdlow
et al., 1994). LI is believed to measure decremental atten-
tion, which is the ability to ignore irrelevant stimuli. Schizo-
phrenics exhibit characteristic abnormalities in LI, espe-
cially when they are acutely symptomatic (Rascle et al.,
2001; Williams et al., 1998). PPI is a common measure of
sensorimotor gating that can be applied to both humans
and mice (Gottesman and Gould, 2003; Arguello and
Gogos, 2006). PPI is characteristically decreased in pa-
tients with schizophrenia (Braff et al., 1992; Grillon et al.,
1992), in schizotypal personality disorder (Cadenhead
et al., 1993), and also in psychosis-prone individuals (Braff
et al., 2001). We observed significant and different deficits
in these and other behavioral measures in the 31L and396 Neuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc.100P mutant mice, as summarized in Table 1. The effects
on sensory processing, as measured by PPI and LI, were
pronounced in 100P/100P and 100P/+ mice and modest,
but still significant, in 31L/31L mutants (Figure 2). The pro-
nounced PPI deficit of compound heterozygous 100P/31L
mice suggests that the 100P mutation is dominant over
both the 31L and wild-type alleles. The capacity of anti-
psychotics and rolipram to improve PPI in 100P/100Pmu-
tants without effects on startle response (Table S1) and
the lack of a correlation between startle response and
PPI in these mice suggest that their low PPI is not merely
a function of low startle. Indeed, several inbred mouse
strains with a low startle response are reported to have
high PPI levels (Paylor and Crawley, 1997). The impair-
ment of both Disc1 missense mutants in a working mem-
ory test (Figure 2H) that was the only behavioral paradigm
to reveal a deficiency in Disc1 deletion carriers (Koike
et al., 2006) suggests that working memory might be par-
ticularly sensitive to Disc1 mutation. The hyperactivity of
100P/100Pmice in the open field resembled the open field
behavior of wild-type rodents given amphetamine (Ralph
et al., 2001).
In the FST, only 31L homozygotes exhibited reduced
mobility (Figure 3). Upon further examination, 31L homo-
zygotes also exhibited reduced sociability and social nov-
elty and reduced reward responsiveness (Figure 3), be-
havioral paradigms that model anhedonia (Cryan and
Holmes, 2005), a key depression symptom characterized
by markedly diminished interest or pleasure in everyday
activities (American Psychiatric Association, 1994).
Pharmacological Responses
The PPI and LI deficits in 100P homozygotes responded to
both typical (haloperidol) and atypical (clozapine) antipsy-
chotics, consistent with a schizophrenic-like phenotype
(Table 1). The PDE4 selective inhibitor rolipram also
substantially rescued the PPI deficit in 100P/100P and in
100P/+ mice but did not alter PPI in 31L mutants or wild-
typemice. Conversely, the biogenic amine reuptake inhib-
itor bupropion was the only drug evaluated that increased
PPI in 31L homozygotes but did not alter PPI in 100P mu-
tants or wild-type mice. Bupropion and rolipram both re-
duced the floating behavior of wild-type mice in the FST,
but intriguingly only bupropion significantly reduced the
floatingbehavior of 31Lhomozygotes. The response to an-
tipsychotics and resistance to bupropion in 100P mutants
and the converse in 31L mutants provides further support
for the notion that the former display schizophrenic-like
and the latter depressive-like phenotypes.
Rolipram is a potent, highly selective inhibitor of PDE4,
the enzyme that specifically catalyzes the hydrolysis of
cAMP (Houslay et al., 2005), a second messenger in
most neuromodulatory systems in the brain. Thus, the
administration of rolipram increases cAMP levels in brain
tissue, which is thought to have behavioral effects via
the consequent upregulation of cAMP signaling in the hip-
pocampus and cerebral cortex (Scheider, 1984; Wachtel,
1983). However, the 50% reduction in cAMP hydrolyzing
Neuron
Disc1 Missense Mutations in MiceTable 1. Summary of Phenotypes of 31L and 100P Disc1Mutant Mice
Phenotype
31L 100P
31L/31L 31L/+ 100P/100P 100P/+
Anxiety (elevated plus-maze) = = = =
Horizontal activity = = >> =
Vertical activity = = > =
Prepulse inhibition (PPI) < = << <<
Acoustic startle response = = < <
Startle reactivity = = < =
Auditory brainstem response n/a n/a = n/a
Latent inhibition (LI) << = << <
Working memory (T maze) < n/a << n/a
Spatial learning and memory (Morris water maze) = = = =
Forced swim immobility (FST) > = = =
Sociability and social novelty < < = =
Sucrose consumption < n/a = n/a
Olfactory function = = = =
Taste sensitivity = n/a n/a n/a
Brain volume < < << <<
PDE4B activity << n/a = n/a
Drug Treatment 31L/31L 31L/+ 100P/100P 100P/+
PPI Clozapine = = + =
Haloperidol = = + =
Rolipram = = +++ ++
Bupropion +++ = = =
LI Clozapine = = + =
Horizontal activity Clozapine +++ n/a ++ n/a
FST Bupropion ++ n/a n/a n/a
Rolipram = n/a n/a n/a
= no significant difference; < lower than +/+; << much lower than +/+; > greater than +/+; >> much greater than +/+; +, ++, +++
positive effect (p < 0.05, p < 0.01, and p < 0.001, respectively); n/a not applied.activity of brain PDE4B, coupled with the rolipram-insen-
sitivity of 31L mutants, suggests that increased cAMP
levels are likely a contributory factor to the depressive-
like behavior of 31L/31L mice. Moreover, the ability of ro-
lipram to reverse the PPI deficits in 100P mutants, which
have normal levels of PDE4B enzymatic activity, suggests
that modulation of PDE4B by DISC1 also underlies some
behavioral abnormalities associated with schizophrenia.
That various dunce mutants of the Drosophila PDE4
gene, each with a profound learning deficit, differ signifi-
cantly in absolute levels of PDE activity and cAMP led to
the conclusion that it is the ability to modulate cAMP,
rather than the baseline amount of cAMP, which is key
for normal memory formation in the fruit fly (Davis and
Kiger, 1981). Our results suggest that the same is true in
mice and by extension abnormal cAMP levels, increasedor decreased, may contribute to psychiatric illness in
humans.
To our knowledge, there are no reports on the efficacy in
mentally ill carriers of the original t(1;11) translocation
(Blackwood et al., 2001) or other putative DISC1 risk al-
leles of anymedication, including the four drugs employed
in our mouse study. However, the different pharmacolog-
ical responses of the 31L and 100P mutant mice might
provide clues to effective medications for these patient
groups. Indeed, these mice could represent a model sys-
tem to explore novel treatment and preventative strate-
gies for certain symptoms of major mental illness.
Abnormal DISC1/PDE4B Interaction
DISC1 abundance and subcellular distribution are indis-
tinguishable from normal in mutant brains, indicatingNeuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc. 397
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rise to the depressive-like and schizophrenic-like pheno-
types of the mutant mice. Indeed, we have demonstrated
that the 31L and 100P mutations each reduce PDE4B
binding to DISC1, while the 31L mutation additionally re-
sults in reduced PDE4B activity, which is not attributable
to altered PDE4B expression, suggesting that altered
DISC1/PDE4B function is fundamentally related to the
phenotypes of both mutants. However, these observa-
tions are at odds with our previous data implying that
decreased binding of PDE4B to DISC1 is likely to result
in increased phosphodiesterase activity (Millar et al.,
2005). This discrepancy is perhaps partially due to our in-
complete understanding of the biochemistry of DISC1/
PDE4B binding. Indeed, we now appreciate that the inter-
action between these two proteins is far more complex
than we previously anticipated, since multiple points of
contact between human DISC1 and PDE4B have recently
been identified (M.D.H., unpublished data). Such multi-
point attachment allows DISC1/PDE4B complexes to
show isoform-specific responses to elevated cAMP levels
(S.M., D.J.P., J.K. Millar, and M.D.H., unpublished data).
This emerging complexity indicates that the differential
impact of the DISC1 mutations upon PDE4B binding,
and possibly also activity, is likely to be crucially related
to their position within distinct contact sites for PDE4B.
Alternatively, the reduced PDE4B activity of 31L mutants
may not be related to the reduced DISC1 binding but
may instead involve the extracellular-regulated kinase
(ERK) pathway that is known to directly regulate PDE4B
catalytic activity by phosphorylation of its catalytic unit
(Baillie et al., 2000). Intriguingly, it was recently demon-
strated that ERK activation is modulated by DISC1 ex-
pression levels in cultured neurons (Hashimoto et al.,
2006; Shinoda et al., 2007); thus, mutant DISC1 may influ-
ence ERK activity leading indirectly to reduced PDE4B
activity in the 31L mutant. Although we can only speculate
upon the molecular causes of the altered PDE4B binding
and activity in the mutants, we have shown that both
DISC1 and PDE4B are abundant in synaptosomes and
postsynaptic density fractions, and consequently it is pos-
sible that the distinctive phenotypes of the 31L and 100P
mutant mice may arise in part from altered synaptic
cAMP signaling.
Conclusion
Wehave shown that two independentmissensemutations
in mouse Disc1 elicit distinct physiological, pharmacolog-
ical, neuroanatomical, and behavioral phenotypes, which
when taken together are strikingly consistent with the
emerging picture from clinical and basic studies of
DISC1 as a common genetic and biologically plausible
risk factor for major mental illness. These mouse models
support both the neurodevelopmental role for DISC1
(Kamiya et al., 2005) and the proposed cAMP signaling
role through modulation of PDE4 activity (Millar et al.,
2005; Porteous et al., 2006). Moreover, by virtue of the
distinct phenotypes of the 31L and 100P mutants, our398 Neuron 54, 387–402, May 3, 2007 ª2007 Elsevier Inc.findings lend further credence to the growing recognition
that schizophrenia and bipolar disorder share, at least
in part, common genetic etiologies and thus underlying
molecular mechanisms (Craddock and Owen, 2005). Our
results in the mouse thus emphasize the importance
of replicating, validating, and resolving inconsistencies
within the current picture of various DISC1 alleles and
haplotypes associating with distinct clinical phenotypes
and, indeed, normal variation in cognitive function and
neurodevelopment (Hennah et al., 2006; Porteous et al.,
2006). By virtue of the complexity of DISC1 interaction
with proteins intimately involved in either neurodevelop-
ment or neuromodulatory signaling (Camargo et al.,
2007), we can predict that secondary genetic factors, epi-
genetic factors, or environmental factors will modify the
phenotypic consequences of any given DISC1 variant.
This is well illustrated by the original t(1;11) family, which
included multiple cases of schizophrenia and multiple
cases of affective disorder, with aminority of translocation
carriers having no recorded signs or symptoms of major
mental illness. However, all those translocation carriers
tested, whatever their clinical status, showed a deficit in
the P300 event-related potential, a brain electrophysiolog-
ical measure of distractedness, characteristic of schizo-
phrenia (Blackwood et al., 2001). The linked hypotheses
that different DISC1 variants will predispose to different
phenotypes and that the phenotype of any given DISC1
variant will be modulated by components within, up-
stream, and downstream of the DISC1 scaffold complex
are now amenable to experimental testing. By extension
of the ENU mutagenesis screen within Exon 2 and
throughout the Disc1 locus, there is scope too for extend-
ing the allelic series to further refine genotype-phenotype
correlations that can inform upon these most complex,
debilitating, and poorly treated disorders.
EXPERIMENTAL PROCEDURES
Mutation Screening
TCGE heteroduplex detection was used to screen 1686 ENU-induced
mutant mice for mutations in Exon 2 of Disc1, as described (Sakuraba
et al., 2005).
Mice
Animal procedures were approved by the Animal Management Com-
mittee of Mount Sinai Hospital and were conducted in accordance
with the requirements of the Ontario Animals for Research Act 1971
and the Canadian Council on Animal Care. Behavioral tests were con-
ducted on sex-balanced groups of experimentally naive mice at 12–16
weeks of age, except where stated. Neither sex effects nor litter effects
were detected by ANOVA in any of the behavioral tests, so data from
different sexes and litters were pooled and analyzed together. Mice
were genotyped for the 31L mutation using a nuclease mismatch
detection protocol (Till et al., 2004) or for the 100P mutation by the
absence of an Hpy188III (New England BioLabs) restriction site.
Behavioral Testing
PPI was measured using acoustic startle, as described (Lipina et al.,
2005). ABR thresholds were recorded using a previously reported al-
gorithm (Zheng et al., 1999). LI was measured by comparing suppres-
sion of drinking in response to a noise by mice that previously received
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followed by two noise/foot shock pairings, as described (Lipina et al.,
2005). Horizontal and vertical activity wasmeasured for 30min in 5min
bins inside a clear Perspex arena (413 413 33 cm) directly illuminated
and equipped with infrared beams to automatically record horizontal
and vertical movements (model 7420/7430, Ugo Basile). The elevated
plus maze test was conducted as described (Avgustinovich et al.,
2000). The discrete paired-trial T-maze task was conducted as de-
scribed (Aultman andMoghaddam, 2001) tomeasureworkingmemory
in male mice that had been food restricted and adapted to the T maze
(two trials for 2 days for 5 min). Spatial learning and memory were as-
sessed in the Morris water maze, using a modification of a previously
described protocol (Clapcote et al., 2005; Supplemental Experimental
Procedures). The FST was conducted as described (Zhang et al.,
2002). The sociability test was conducted as described (Moy et al.,
2004) using apparatus consisting of a black Perspex rectangular box
(51 cm long 3 25.5 cm wide 3 23 cm tall) divided into three intercon-
nected chambers, as described (Sankoorikal et al., 2006). Olfactory
ability was assessed by measuring latency to find a buried piece of
food, as described (Stowers et al., 2002). The consumption of water
and sucrose solution was measured by weighing the drinking bottles,
as described (Pothion et al., 2004). Selection of the 10% concentration
was based the reported preference of C57BL/6J mice for a sucrose
solution at this concentration (Pothion et al., 2004). In a control exper-
iment, baseline water intake of individually housed mice was recorded
every 48 hr over 10 days. Water bottles were then replaced every 2
days with one of six different concentrations of freshly made sucrose
solution (0.5%, 1%, 2%, 4%, 8% and 16%, weight/volume concentra-
tion) or water (0%), as described (Sakic et al., 1996).
Drug Administration
Drugs were administered by i.p. injection in a volume of 10 ml/kg 30
min before the commencement of the behavioral procedure. Cloza-
pine (3 mg/kg; Tocris) and haloperidol (0.4 mg/kg; Tocris) were each
dissolved in saline (0.9% NaCl) containing 0.3% Tween 20 (Bio-Rad).
Bupropion (4 mg/kg; Sigma) was dissolved in distilled water. Rolipram
(0.5mg/kg; Sigma) was dissolved in saline containing 10%DMSO. The
clozapine dose was selected from our previous study of C57BL/6J
mice (Lipina et al., 2005). The doses of bupropion, haloperidol, and ro-
lipramwere determined by reference to previous rodent studies (David
et al., 2003; Egashira et al., 2005; Pouzet et al., 2005; Zhang et al.,
2002). In the LI experiment, clozapine was administered in both the
pre-exposure and conditioning stages. In the FST, we injected mice
with rolipram daily for 8 days and commenced testing 30 min after
the last injection.
Magnetic Resonance Imaging
A four-channel 7.0-Tesla MR scanner (Varian) with a 6 cm inner bore
diameter gradient set was used to acquire anatomical images of brains
within skulls. The 3DMR imageswere initially aligned to one another by
automated linear registration, as described (Chen et al., 2006; Kova-
cevic et al., 2005). Owing to the limited number of mice in each geno-
type group, we combined homozygotes and heterozygotes from each
mutant line into single 31L or 100P groups (n = 12) to increase statisti-
cal power in comparisons with the wild-type group (n = 6).
Immunoblotting and Subcellular Fractionation
Whole brain extracts or subcellular fractions were subjected to SDS-
PAGE and then immunoblotting analyses by incubation with indicated
antibodies overnight at 4C. Dilution of primary antibodies in 1%
skimmed milk was as follows: DISC1 C-terminal polyclonal antibody
ZMD.488 (Invitrogen; 1:250 for whole brain; 1:2000 for fractions);
mouse anti-PSD-95 monoclonal antibody, clone 7E3-1B8 (ABR;
1:5000); mouse anti-synaptophysin monoclonal antibody, clone
SVP38 (Sigma; 1:10,000), sheep anti-pan PDE4B polyclonal antibody
(1:30,000). Subcellular fractionations were carried out as described(Ueda et al., 1979; Niethammer et al., 2000; Okabe et al., 2003), with
a slight modification (Supplemental Experimental Procedures).
Binding Assays
Mutations Q31L and L100P were introduced into pRK5-HADisc1 (a gift
from A. Sawa) using the QuikChange II Site-Directed Mutagenesis Kit
(Stratagene). Lysates were prepared from transfected HEK293 cells
expressing various combinations of wild-type mouse DISC1 or
DISC1 mutants (Q31L and L100P) and FLAG-tagged PDE4B1 or
PDE4B3 (Millar et al., 2005). For immunoprecipitation experiments,
mouse monoclonal anti-FLAG M2 (Sigma) or sheep polyclonal pan-
PDE4B (Huston et al., 1997) antibodies were added to initiate capture
of PDE4B complexes. Levels of immunoprecipitated PDE4B and asso-
ciated DISC1 were determined by probing immunoblots of the sam-
ples with sheep polyclonal pan-PDE4B antibody (1:40,000) or rabbit
polyclonal antibody ZMD.488 (1:500; Invitrogen).
PDE4B Activity
The activity of PDE4B selectively immunoprecipitated from whole-
brain lysates was assayed as described (Marchmont and Houslay,
1980).
Further details of all experimental procedures are provided in the
Supplemental Data.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/54/3/387/DC1/.
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